SPDR Advertisement SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator bulldurham, TopPenny, Peacefulwendy, TheBestInvest, PetePham, KitchenRat
Search This Board:
Last Post: 3/4/2015 4:59:52 PM - Followers: 516 - Board type: Free - Posts Today: 44

Welcome to PharmaCyte BioTech
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

http://www.nuvilex.com/latest-news/149-fda-grants-orphan-drug-designation-to-nuvilex-for-pancreatic-cancer-treatment



Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

http://www.mdpi.com/1999-4923/6/3/447




















ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

http://www.youtube.com/watch?v=nL_LznwTdKk


Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award
 
http://client.irwebkit.com/Nuvilex/news/2433458






Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers


http://austrianova.com/wp-content/uploads/2014/09/DRTOA-1-102-final.compressed.pdf


NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)

                                            

PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email:
 info@pharmacytebiotech.com


Market Value:
$162,381,784 a/o Oct 31, 2014

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

Float:
529,206,849 a/o Aug 26, 2014


Short Selling Data

Short Interest: 8,450,144 a/o Aug 29, 2014

For more updated information please visit: 


http://www.otcmarkets.com/stock/PMCB/profile


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations


Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 
jjones@bplifescience.com 

http://bplifescience.com/clients.html 

                                               

All News Releases: 
http://www.nuvilex.com/latest-news

All Information about Nuvilex:
http://www.stockmarketmediagroup.com/features/nvlx/

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


http://austrianova.com/products/ 



PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.



">

Austria Nova Demonstration Video

 
 

SMMG Radio Interview with COO Dr. Crabtree ~ 2013





Shareholder Update with CEO & COO via SMMG Interview ~ July 2014






The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool


Management Team:

 

Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

 

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:



Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:



Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.


Dr. Matthias Lohr as Chairman of Scientific Advisory Board:



Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.



Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0

Features http://www.stockmarketmediagroup.com/features/nvlx/

 

                                  

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB
Current Price
Volume:
Bid Ask Day's Range
Wiki
NVLX News: Current Report Filing (8-k) 01/09/2015 11:34:14 AM
NVLX News: Nuvilex Announces Name Change to PharmaCyte Biotech 01/07/2015 09:30:00 AM
NVLX News: Nuvilex to Attend 2015 Gastrointestinal Cancers Symposium in San Francisco, January 15-17, 2015 01/06/2015 09:30:00 AM
NVLX News: FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment 12/22/2014 08:30:00 AM
NVLX News: Nuvilex’s Partner Austrianova Successfully Completes First Live-Cell Encapsulation in New Facility 12/18/2014 09:30:00 AM
PostSubject
#31958  Sticky Note PharmaCyte Biotech Initiates Expanded Follow-up Study in the bulldurham 02/19/15 09:31:41 AM
#31934  Sticky Note This is why Nuvilex and it's proprietary cellulose-based Peacefulwendy 02/15/15 01:59:39 PM
#31803  Sticky Note $PMCB FOLKS (READ HERE: DD).... PetePham 02/11/15 07:45:42 PM
#31423  Sticky Note PharmaCyte Biotech Initiates First Preclinical Study of Its TheBestInvest 02/04/15 11:38:18 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#32376   Wow...MICK has 15 years + of experiences and PetePham 03/04/15 04:59:52 PM
#32374   Great info MICK Go $PMCB PetePham 03/04/15 04:30:52 PM
#32373   48 Marijuana Stocks - A Post-Mortem: Part I mick 03/04/15 04:27:06 PM
#32372   great support today/\ Pharmacyte Biotech, (PMCB) mick 03/04/15 04:24:50 PM
#32371   Not today. Looks as if bottom gun drop HighHoeSilverado 03/04/15 04:17:14 PM
#32370   $PMCB [IMG]http://i1380.photobucket.com/albums/ah161/phulinh1/Mobile%20Uploads PetePham 03/04/15 03:09:39 PM
#32369   Wow...now everyone knew that...and PMCB will be a PetePham 03/04/15 01:54:46 PM
#32368   no need for a stop loss I have thenewmixer 03/04/15 01:51:55 PM
#32367   Hang in there if you still believe in PetePham 03/04/15 01:48:57 PM
#32366   if Big Pharma thought PMCB had anything going thenewmixer 03/04/15 01:46:01 PM
#32365   Big Pharma has money and they will buy PetePham 03/04/15 01:42:57 PM
#32364   Who sells the future of the medical industry LuCo 03/04/15 01:41:58 PM
#32363   Same here my Friend. Go $PMCB Pistol Pete! PetePham 03/04/15 01:34:52 PM
#32362   i like today's uptick trading/ mick 03/04/15 01:33:29 PM
#32361   Thanks MICK. Big bounce back soon Go $PMCB PetePham 03/04/15 01:32:20 PM
#32360   I agree with you that pmcb is not avenger9691 03/04/15 01:32:04 PM
#32359   rally time/ stockcharts.com/c-sc/sc?s=pmcb&p=30&yr=0&mn=0&dy=3&i=p5455131 mick 03/04/15 01:31:40 PM
#32358   If they believe in Hoff they would have lastcall59 03/04/15 01:29:59 PM
#32357   If cell in the box did not show avenger9691 03/04/15 01:27:09 PM
#32356   and if work in the medical field then thenewmixer 03/04/15 01:25:32 PM
#32355   we have been waiting for Von Hoffs report thenewmixer 03/04/15 01:21:46 PM
#32354   How can you say the science has failed? avenger9691 03/04/15 01:17:27 PM
#32353   Prove it Go $PMCB PetePham 03/04/15 01:17:06 PM
#32352   I am here Pete I got your back, yeahright231 03/04/15 01:16:38 PM
#32351   PPS mean nothing. Once the right news hit, PetePham 03/04/15 01:11:11 PM
#32350   it seem you are the only one dreaming thenewmixer 03/04/15 01:08:59 PM
#32349   PMCB The Science has failed if the pps thenewmixer 03/04/15 01:07:01 PM
#32348   Keep dreaming and dreaming my Friend $PMCB will be PetePham 03/04/15 01:05:25 PM
#32347   since PMCB 52 week high will be doping thenewmixer 03/04/15 01:03:45 PM
#32346   Hey MICK, I think $PMCB will hit to 52 PetePham 03/04/15 12:53:51 PM
#32345   I Agree... Newbigtech 03/04/15 12:51:26 PM
#32344   Hopefully you are study the New Technology and PetePham 03/04/15 12:46:15 PM
#32343   Regardless of who owned what.. Science has changed.. Newbigtech 03/04/15 12:46:07 PM
#32342   Very nice post, Newbigtech... Peacefulwendy 03/04/15 12:38:03 PM
#32341   Well see that's pretty incorrect. Bavarian Nordic owned Hotelier51 03/04/15 12:35:10 PM
#32340   And as the History goes, No one was Newbigtech 03/04/15 12:26:18 PM
#32339   To remind people: Cell-in-a-Box dates back to 1996 Hotelier51 03/04/15 12:10:31 PM
#32338   Let u tell it. We are at the HighHoeSilverado 03/04/15 11:41:45 AM
#32337   Same here my Friend. I will load the PetePham 03/04/15 11:25:21 AM
#32335   GREAT!!! I am ready to jump right in rball 03/04/15 11:14:37 AM
#32334   Single digits here soon. Alydyr 03/04/15 11:09:01 AM
#32333   PMCB 1st quarter count down continues still nothing thenewmixer 03/04/15 09:41:36 AM
#32332   today's trading is storyteller/\ mick 03/03/15 08:20:38 PM
#32331   You can't really say yes or no \ HighHoeSilverado 03/03/15 08:11:07 PM
#32330   today's trading had lot of double btms/\ pmcb mick 03/03/15 08:03:40 PM
#32329   Chart is surprisingly, devilishly misleading because it does HighHoeSilverado 03/03/15 07:51:29 PM
#32328   i think ready to roll good chart read/\ mick 03/03/15 07:48:02 PM
#32327   o.k. look closely at recent charting/\ mick 03/03/15 07:45:50 PM
#32326   "Pay Exercised  HighHoeSilverado 03/03/15 07:43:51 PM
#32325   p&f has P.P.O. $0.37/ 0.15 WILL COMPLETE *w* mick 03/03/15 07:41:06 PM
PostSubject